71 results on '"Zangwill KM"'
Search Results
2. PIH19 - Management of Asymptomatic Term & Late Preterm Newborns Exposed to Maternal Intrapartum Fever: A Societal Cost Benefit Analysis of the Proposed “Triple I” Algorithm
- Author
-
Gong, CL, Dasgupta-Tsinikas, S, Zangwill, KM, Bolaris, M, and Hay, JW
- Published
- 2018
- Full Text
- View/download PDF
3. Cost-benefit analysis of in-hospital influenza vaccination of postpartum women.
- Author
-
Ding Y, Zangwill KM, Hay JW, Allred NJ, and Yeh SH
- Published
- 2012
- Full Text
- View/download PDF
4. Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subirion H5N1 influenza vaccine in humans.
- Author
-
Zangwill KM, Treanor JJ, Campbell JD, Noah DL, and Ryea J
- Abstract
Previously, we evaluated 2 doses of H5N1 influenza vaccine in persons 18-64 years of age (placebo and 7.5-, 15-, 45-, or 90-microg doses), separated by 28 days. In this study, 337 participants received a third dose, 6 months thereafter. Microneutralization (MN) and hemagglutination-inhibition geometric mean titers (GMTs) of antibody declined before the third dose. Twenty-eight days after the third dose, 78%, 67%, 43%, and 31% of recipients in the 90-, 45-, 15-, and 7.5-mug-dose groups had a MN GMT > or =1:40, respectively. Five months later, MN GMTs were significantly greater than those after the second dose. (Trial registration: Clinical Trials.gov identifier NCT00240968 .). Copyright © 2008 The Hospital Infection Society [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
5. Varicella vaccination and ischemic stroke in children: is there an association?
- Author
-
Donahue JG, Kieke BA, Yih WK, Berger NR, McCauley JS, Baggs J, Zangwill KM, Baxter R, Eriksen EM, Glanz JM, Hambidge SJ, Klein NP, Lewis EM, Marcy SM, Naleway AL, Nordin JD, Ray P, Belongia EA, and Vaccine Safety DataLink Team
- Published
- 2009
- Full Text
- View/download PDF
6. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.
- Author
-
Treanor JJ, Campbell JD, Zangwill KM, Rowe T, and Wolff M
- Published
- 2006
7. Response to "Estimating the cost of inappropriate antibiotic prophylaxis prior to dental procedures".
- Author
-
Gong CL, Duong AP, and Zangwill KM
- Subjects
- Humans, Dentistry, Antibiotic Prophylaxis, Endocarditis, Bacterial
- Published
- 2024
- Full Text
- View/download PDF
8. SHEA NICU white paper series: Practical approaches for the prevention of viral respiratory infections.
- Author
-
Thampi N, Guzman-Cottrill J, Bartlett AH, Berg W, Cantey JB, Kitt E, Ravin K, Zangwill KM, and Elward A
- Abstract
This white paper provides clinicians and hospital leaders with practical guidance on the prevention and control of viral respiratory infections in the neonatal intensive care unit (NICU). This document serves as a companion to Centers for Disease Control and Prevention Healthcare Infection Control Practices Advisory Committee (HICPAC)'s "Prophylaxis and Screening for Prevention of Viral Respiratory Infections in Neonatal Intensive Care Unit Patients: A Systematic Review." It provides practical, expert opinion and/or evidence-based answers to frequently asked questions about viral respiratory detection and prevention in the NICU. It was developed by a writing panel of pediatric and pathogen-specific experts who collaborated with members of the HICPAC systematic review writing panel and the SHEA Pediatric Leadership Council to identify questions that should be addressed. The document has been endorsed by SHEA, the American Hospital Association (AHA), The Joint Commission, the Pediatric Infectious Diseases Society (PIDS), the Association for Professionals in Infection Control and Epidemiology (APIC), the Infectious Diseases Society of America (IDSA), and the National Association of Neonatal Nurses (NANN).
- Published
- 2024
- Full Text
- View/download PDF
9. Changes in perceptions of antibiotic stewardship among neonatal intensive care unit providers over the course of a learning collaborative: a prospective, multisite, mixed-methods evaluation.
- Author
-
Qureshi N, Kroger J, Zangwill KM, Joshi NS, Payton K, and Mendel P
- Subjects
- Infant, Newborn, Humans, Prospective Studies, Anti-Bacterial Agents therapeutic use, Surveys and Questionnaires, Intensive Care Units, Neonatal, Antimicrobial Stewardship
- Abstract
Objective: To assess clinician perceptions towards the value and implementation of antibiotic stewardship (AS) in neonatal intensive care units (NICU)., Study Design: We performed a mixed-methods study of AS perceptions (prescribing appropriateness, importance, activity, capacity) using surveys and interviews in 30 California NICUs before and after a multicenter collaborative (Optimizing Antibiotic Use in California NICUs [OASCN])., Results: Pre-OASCN, 24% of respondents felt there was "a lot of" or "some" inappropriate prescribing, often driven by fear of a bad outcome or reluctance to change existing practice. Clinicians reported statistically significant increases in AS importance (71 v 79%), perceived AS activity (67 v 87%), and more openness to change after OASCN (59 v 70%). We identified other concerns that lessen AS effort., Conclusion: OASCN increased perceived AS activity and openness to change in AS practices among NICU prescribers. Greater attention to subjective concerns should augment AS improvement., (© 2023. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
10. Estimating the cost of inappropriate antibiotic prophylaxis prior to dental procedures.
- Author
-
Gong CL, Duong A, and Zangwill KM
- Subjects
- Humans, United States, Antibiotic Prophylaxis adverse effects, Anti-Bacterial Agents therapeutic use, Amoxicillin, Dentistry, Endocarditis, Bacterial, Endocarditis etiology, Endocarditis prevention & control
- Abstract
Inappropriate dental antibiotic prescriptions to prevent infective endocarditis in the United States results in ∼$31 million in excess costs to the healthcare system and patients. This includes out-of-pocket costs ($20.5 million), drug costs ($2.69 million) and adverse event costs (eg, Clostridioides difficile and hypersensitivity) of $5.82 million (amoxicillin), $1.99 million (clindamycin), and $380,849 (cephalexin).
- Published
- 2023
- Full Text
- View/download PDF
11. Blood culture procedures and practices in the neonatal intensive care unit: A survey of a large multicenter collaborative in California.
- Author
-
Lefrak L, Schaffer KE, Bohnert J, Mendel P, Payton KSE, Lee HC, Bolaris MA, and Zangwill KM
- Subjects
- Infant, Newborn, Pregnancy, Female, Humans, Surveys and Questionnaires, California, Outcome Assessment, Health Care, Intensive Care Units, Neonatal, Blood Culture
- Abstract
Objective: To describe variation in blood culture practices in the neonatal intensive care unit (NICU)., Design: Survey of neonatal practitioners involved with blood culturing and NICU-level policy development., Participants: We included 28 NICUs in a large antimicrobial stewardship quality improvement program through the California Perinatal Quality Care Collaborative., Methods: Web-based survey of bedside blood culture practices and NICU- and laboratory-level practices. We evaluated adherence to recommended practices., Results: Most NICUs did not have a procedural competency (54%), did not document the sample volume (75%), did not receive a culture contamination report (57%), and/or did not require reporting to the provider if <1 mL blood was obtained (64%). The skin asepsis procedure varied across NICUs. Only 71% had a written procedure, but ≥86% changed the needle and disinfected the bottle top prior to inoculation. More than one-fifth of NICUs draw a culture from an intravascular device only (if present). Of 13 modifiable practices related to culture and contamination, NICUs with nurse practitioners more frequently adopted >50% of practices, compared to units without (92% vs 50% of units; P < .02)., Conclusions: In the NICU setting, recommended practices for blood culturing were not routinely performed.
- Published
- 2023
- Full Text
- View/download PDF
12. Accurate subspecies-level identification of clinically significant Mycobacterium avium and Mycobacterium intracellulare by whole-genome sequencing.
- Author
-
Chawla R, Shaw B, von Bredow B, Chong C, Garner OB, Zangwill KM, and Yang S
- Subjects
- Animals, Humans, Mycobacterium avium Complex genetics, Mycobacterium avium genetics, Whole Genome Sequencing, Mycobacterium avium-intracellulare Infection diagnosis, Mycobacterium avium-intracellulare Infection microbiology, Paratuberculosis
- Abstract
Whole genome sequencing (WGS) of Mycobacterium avium complex (MAC) isolates in the clinical laboratory setting allows for rapid and reliable subspecies identification of a closely related complex of human pathogens. We developed a bioinformatics pipeline for accurate subspecies identification and tested 74 clinical MAC isolates from various anatomical sites. We demonstrate that reliable subspecies level identification of these common and clinically significant MAC isolates, including M. avium subsp. hominissuis (most dominant in causing lower respiratory tract infections in our cohort), M. avium subsp. avium, M. intracellulare subsp. intracellulare, and M. intracellulare subsp. chimaera, can be achieved by analysis of only two marker genes (rpoB and groEL/hsp65). We then explored the relationship between these subspecies and anatomical site of infection. Further, we conducted an in silico analysis and showed our algorithm also performed well for M. avium subsp. paratuberculosis but failed to consistently identify M. avium subsp. silvaticum and M. intracellulare subsp. yongonense, likely due to a lack of available reference genome sequences; all the 3 subspecies were not found in our clinical isolates and rarely reported to cause human infections. Accurate MAC subspecies identification may provide the tool and opportunity for better understanding of the disease-subspecies dynamics in MAC infections., Competing Interests: Declaration of Competing Interest There are no conflicts of interest., (Copyright © 2023 Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
13. SHEA Neonatal Intensive Care Unit (NICU) White Paper Series: Practical approaches for the prevention of central-line-associated bloodstream infections.
- Author
-
Muller M, Bryant KA, Espinosa C, Jones JA, Quach C, Rindels JR, Stewart DL, Zangwill KM, and Sánchez PJ
- Subjects
- Infant, Infant, Newborn, Humans, Child, Intensive Care Units, Neonatal, Infection Control methods, Catheter-Related Infections prevention & control, Staphylococcal Infections complications, Sepsis
- Abstract
This document is part of the "SHEA Neonatal Intensive Care Unit (NICU) White Paper Series." It is intended to provide practical, expert opinion, and/or evidence-based answers to frequently asked questions about CLABSI detection and prevention in the NICU. This document serves as a companion to the CDC Healthcare Infection Control Practices Advisory Committee (HICPAC) Guideline for Prevention of Infections in Neonatal Intensive Care Unit Patients. Central line-associated bloodstream infections (CLABSIs) are among the most frequent invasive infections among infants in the NICU and contribute to substantial morbidity and mortality. Infants who survive CLABSIs have prolonged hospitalization resulting in increased healthcare costs and suffer greater comorbidities including worse neurodevelopmental and growth outcomes. A bundled approach to central line care practices in the NICU has reduced CLABSI rates, but challenges remain. This document was authored by pediatric infectious diseases specialists, neonatologists, advanced practice nurse practitioners, infection preventionists, members of the HICPAC guideline-writing panel, and members of the SHEA Pediatric Leadership Council. For the selected topic areas, the authors provide practical approaches in question-and-answer format, with answers based on consensus expert opinion within the context of the literature search conducted for the companion HICPAC document and supplemented by other published information retrieved by the authors. Two documents in the series precede this one: "Practical approaches to Clostridioides difficile prevention" published in August 2018 and "Practical approaches to Staphylococcus aureus prevention," published in September 2020.
- Published
- 2023
- Full Text
- View/download PDF
14. Treatment and Epidemiology of Third-Generation Cephalosporin-Resistant Urinary Tract Infections.
- Author
-
Dasgupta-Tsinikas S, Zangwill KM, Nielsen K, Lee R, Friedlander S, Donovan SM, Van TT, Butler-Wu SM, Batra JS, and Yeh SH
- Subjects
- Anti-Bacterial Agents therapeutic use, Cephalosporins therapeutic use, Child, Humans, United States epidemiology, Urinalysis, Anti-Infective Agents therapeutic use, Urinary Tract Infections complications, Urinary Tract Infections drug therapy, Urinary Tract Infections epidemiology
- Abstract
Background and Objectives: Limited data are available on the contemporary epidemiology, clinical management, and health care utilization for pediatric urinary tract infection (UTI) due to third-generation cephalosporin-resistant Enterobacterales (G3CR) in the United States. The objective is to describe the epidemiology, antimicrobial treatment and response, and health care utilization associated with G3CR UTI., Methods: Multisite, matched cohort-control study including children with G3CR UTI versus non-G3CR UTI. UTI was defined as per American Academy of Pediatrics guidelines, and G3CR as resistance to ceftriaxone, cefotaxime, or ceftazidime. We collected data from the acute phase of illness to 6 months thereafter., Results: Among 107 children with G3CR UTI and 206 non-G3CR UTI with documented assessment of response, the proportion with significant improvement on initial therapy was similar (52% vs 57%; odds ratio [OR], 0.81; 95% confidence interval [CI], 0.44-1.50). Patients with G3CR were more frequently hospitalized at presentation (38% vs 17%; OR, 3.03; 95% CI, 1.77-5.19). In the follow-up period, more patients with G3CR had urine cultures (75% vs 53%; OR, 2.61; 95% CI, 1.33-5.24), antimicrobial treatment of any indication (53% vs 29%; OR, 2.82; 95% CI, 1.47-5.39), and subspecialty consultation (23% vs 6%; OR, 4.52; 95% CI, 2.10-10.09). In multivariate analysis, previous systemic antimicrobial therapy remained a significant risk factor for G3CR UTI (adjusted OR, 1.91; 95% CI, 1.06-3.44)., Conclusions: We did not observe a significant difference in response to therapy between G3CR and susceptible UTI, but subsequent health care utilization was significantly increased., (Copyright © 2022 by the American Academy of Pediatrics.)
- Published
- 2022
- Full Text
- View/download PDF
15. Is Acute Solid Food Aversion a Proxy for COVID-19-Related Olfactory and Gustatory Dysfunction?
- Author
-
Tseng FH, Yeh SH, Basiago K, Miyares W, and Zangwill KM
- Published
- 2021
- Full Text
- View/download PDF
16. Cat Scratch Disease and Bartonellaceae: The Known, the Unknown and the Curious.
- Author
-
Zangwill KM
- Subjects
- Angiomatosis, Bacillary pathology, Animals, Bartonella Infections history, Cat-Scratch Disease pathology, Disease Management, Disease Reservoirs, Disease Vectors, History, 20th Century, Humans, Trench Fever pathology, Bartonella pathogenicity, Bartonella Infections epidemiology, Bartonella Infections pathology
- Abstract
Since the early 1900s, Bartonella species were known only to cause human disease resulting from very restricted geographic (bartonellosis) or environmental influences ("trench fever"). In the 1990s, and in parallel, cat scratch disease and bacillary angiomatosis were definitively linked to Bartonella species. Subsequently, widespread use of modern diagnostic methods revealed the broad ecologic niche of this organism and greatly expanded our knowledge of the epidemiology and clinical presentations associated with this genus. A large number of reservoirs and vectors involved with Bartonella propagation and transmission to humans have been identified; cats and various arthropods remain the most well-studied to date. Though not completely understood, it appears that specific immune-modulated interactions between the infecting species and host-related factors play a major role in the observed breadth of human clinical syndromes associated with Bartonellae, the large differences in immunopathologic features of tissue samples among different syndromes and potentially the varied responses to antimicrobial therapy. Further, the clinical management for cat scratch disease in particular is quite variable among clinicians, reflecting a poor evidence base. No preventive measures have been developed beyond suggestions to avoid at-risk behavior with known vectors., Competing Interests: The authors have no funding or conflicts of interest to disclose., (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
17. SHEA neonatal intensive care unit (NICU) white paper series: Practical approaches to Staphylococcus aureus disease prevention.
- Author
-
Akinboyo IC, Zangwill KM, Berg WM, Cantey JB, Huizinga B, and Milstone AM
- Subjects
- Humans, Infant, Newborn, Staphylococcus aureus, Cross Infection, Intensive Care Units, Neonatal, Methicillin-Resistant Staphylococcus aureus, Staphylococcal Infections prevention & control
- Published
- 2020
- Full Text
- View/download PDF
18. Under-allocation: Critical Supply Chain Hurdles Negatively Impact the Ability of Community Hospitals To Perform Repeat SARS-CoV-2 Testing.
- Author
-
Butler-Wu SM, Wald-Dickler N, Holtom P, Zangwill KM, and Van TT
- Subjects
- COVID-19, COVID-19 Testing, Clinical Laboratory Techniques, Coronavirus Infections diagnosis, Hospitals, Community, Humans, SARS-CoV-2, Betacoronavirus, Coronavirus Infections epidemiology, Pandemics, Pneumonia, Viral
- Published
- 2020
- Full Text
- View/download PDF
19. Epidemiology of Admissions From the Emergency Department Among Febrile Infants Younger Than 90 Days in the United States, 2002 to 2012.
- Author
-
Nguyen DK, Fleischman RJ, Friedlander S, and Zangwill KM
- Subjects
- Bacterial Infections diagnosis, Emergency Service, Hospital, Female, Fever ethnology, Fever etiology, Humans, Infant, Infant, Newborn, Male, Retrospective Studies, United States epidemiology, Fever epidemiology, Hospitalization statistics & numerical data
- Abstract
Background and Objectives: Febrile infants younger than 90 days are often subjected to invasive diagnostic evaluation and hospitalization to monitor for serious bacterial infection (SBI) despite recent changes in SBI risk and advances in diagnostics. Nationwide provider practices, over time, are unknown for this group. Our objective was to determine the likelihood of admission and associated complications of care for such infants, particularly those at lowest risk for SBI., Methods: This is a retrospective cohort study including multisite emergency department (ED) visits using administrative data from the Pediatric Emergency Care Applied Research Network Core Data Project. We examined uncomplicated febrile infants younger than 90 days seen in the ED from 2002 to 2012 who did not have an explicit infectious diagnosis, critical illness, or chronic condition., Results: We identified 38,224 infants, among whom, 11,600 (31%) were admitted. We observed a 3% increase in ED admission every year during the study period (P < 0.05). Age less than 30 days and black race were independent predictors of admission (P < 0.01). We identified 227 complications of care in the ED. Among those with a specified cause, 49% were attributed to antibiotic use or procedures related to the diagnosis and empiric treatment of suspected infection., Conclusions: Despite the decreasing risk of SBI and diagnostic advances during the study period, the odds of hospital admission increased for febrile infants at low risk for sepsis. We also provide first data on therapeutic and diagnostic test-related adverse events in this setting. These data provide further justification for a consensus guideline on management of such infants.
- Published
- 2020
- Full Text
- View/download PDF
20. A Case of Langerhans Cell Histiocytosis With Multifocal, Single-System GI Tract Involvement and Literature Review.
- Author
-
Gotesman M, Getachew R, Morales S, Zangwill KM, Gershman G, Lee S, Lasky JL 3rd, and Panosyan EH
- Subjects
- Adult, Antimetabolites, Antineoplastic therapeutic use, Cytarabine therapeutic use, Female, Gastrointestinal Diseases complications, Gastrointestinal Diseases drug therapy, Histiocytosis, Langerhans-Cell complications, Histiocytosis, Langerhans-Cell drug therapy, Humans, Prognosis, Young Adult, Gastrointestinal Diseases pathology, Histiocytosis, Langerhans-Cell pathology
- Abstract
Langerhans cell histiocytosis (LCH) is the most common histiocytic disorder, characterized by the pathologic clonal proliferation and accumulation of immature Langerhans cells within organs. Multiple organ systems can be affected, resulting in a spectrum of clinical manifestations. Isolated gastrointestinal involvement in LCH is rare and usually presents in childhood as a multisystem disease and usually has poor outcomes. We describe a 20-year-old Hispanic female with multifocal, single-system gastrointestinal LCH. Initially diagnosed from a CD1a, S100, and CD207 (Langerin) positive appendix tissue after an appendectomy and confirmed multifocal with an endoscopy. She had a full clinical and endoscopic resolution of disease with cytarabine therapy.
- Published
- 2020
- Full Text
- View/download PDF
21. Cost-Effectiveness Analysis of Four Common Diagnostic Methods for Clostridioides difficile Infection.
- Author
-
Xuan S, Zangwill KM, Ni W, Ma J, and Hay JW
- Subjects
- Aged, Clostridioides, Cost-Benefit Analysis, Humans, Immunoenzyme Techniques, Clostridioides difficile, Clostridium Infections diagnosis, Clostridium Infections epidemiology
- Abstract
Background: No studies have evaluated the cost-effectiveness of single and two-step different diagnostic test strategies for Clostridioides difficile infection (CDI), including direct and indirect costs., Objective: To evaluate the cost-effectiveness of commonly available diagnostic tests for CDI including nucleic acid amplification testing (NAAT) alone, glutamate dehydrogenase followed by enzyme immunoassay for toxin (GDH/EIA), GDH then NAAT (GDH/NAAT), and NAAT then EIA (NAAT/EIA)., Design: Decision tree model from the US societal perspective with inputs derived from the literature. Willingness-to-pay threshold was set at $150,000 per quality-adjusted life year (QALY) gained. To assess the impact of uncertainty in model inputs on the findings, we performed one-way and probabilistic sensitivity analyses., Participants: We conducted the analysis to represent a population aged 65 years old with diarrhea who received a CDI diagnostic test., Main Measures: Incremental cost-effectiveness ratios (ICER) and incremental net monetary benefits (INMB)., Key Results: NAAT alone was the most cost-effective approach overall; GDH/NAAT was the most cost-effective two-step option. NAAT alone led to the highest QALYs gained, at an incremental cost of $54,547 (vs. GDH/NAAT), $55,410 (vs. GDH/EIA), and $50,231 (vs. NAAT/EIA) per QALY gained. NAAT/EIA was not cost-effective compared to any other strategy. GDH/NAAT resulted in a higher QALY compared to GDH/EIA, at an incremental cost of $96,841 per QALY gained. Variability in the likelihood of comorbidities, CDI probability, and age at disease onset did not substantially change the results. One-way sensitivity analyses showed that results were most sensitive to likelihood of recurrence, followed by CDI mortality rate and probability of severe CDI. Probabilistic sensitivity analyses explored known uncertainties in the base case and confirmed the robustness of the results., Conclusions: NAAT alone and GDH/NAAT (among the two-step options) were the most cost-effective diagnostic test approaches for CDI.
- Published
- 2020
- Full Text
- View/download PDF
22. Behavioral Economics Interventions to Improve Outpatient Antibiotic Prescribing for Acute Respiratory Infections: a Cost-Effectiveness Analysis.
- Author
-
Gong CL, Zangwill KM, Hay JW, Meeker D, and Doctor JN
- Subjects
- Adult, Behavior Therapy, Case-Control Studies, Clinical Decision-Making, Cost-Benefit Analysis, Humans, Inappropriate Prescribing economics, Markov Chains, Middle Aged, Practice Patterns, Physicians' economics, Quality-Adjusted Life Years, Respiratory Tract Infections economics, Young Adult, Inappropriate Prescribing prevention & control, Respiratory Tract Infections drug therapy
- Abstract
Background: Behavioral economics interventions have been shown to effectively reduce the rates of inappropriate antibiotic prescriptions for acute respiratory infections (ARIs)., Objective: To determine the cost-effectiveness of three behavioral economic interventions designed to reduce inappropriate antibiotic prescriptions for ARIs., Design: Thirty-year Markov model from the US societal perspective with inputs derived from the literature and CDC surveillance data., Subjects: Forty-five-year-old adults with signs and symptoms of ARI presenting to a healthcare provider., Interventions: (1) Provider education on guidelines for the appropriate treatment of ARIs; (2) Suggested Alternatives, which utilizes computerized clinical decision support to suggest non-antibiotic treatment choices in lieu of antibiotics; (3) Accountable Justification, which mandates free-text justification into the patient's electronic health record when antibiotics are prescribed; and (4) Peer Comparison, which sends a periodic email to prescribers about his/her rate of inappropriate antibiotic prescribing relative to clinician colleagues., Main Measures: Discounted costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios., Key Results: Each intervention has lower costs but higher QALYs compared to provider education. Total costs for each intervention were $178.21, $173.22, $172.82, and $172.52, and total QALYs were 14.68, 14.73, 14.74, and 14.74 for the control, Suggested Alternatives, Accountable Justification, and Peer Comparison groups, respectively. Results were most sensitive to the quality-of-life of the uninfected state, and the likelihood and costs for antibiotic-associated adverse events., Conclusions: Behavioral economics interventions can be cost-effective strategies for reducing inappropriate antibiotic prescriptions by reducing healthcare resource utilization.
- Published
- 2019
- Full Text
- View/download PDF
23. Diagnosis of congenital/perinatal infections by neonatologists: a national survey.
- Author
-
Hwang JS, Friedlander S, Rehan VK, and Zangwill KM
- Subjects
- Clinical Decision-Making, Cytomegalovirus Infections diagnosis, Female, Herpes Simplex diagnosis, Humans, Infant, Newborn, Logistic Models, Multivariate Analysis, Practice Patterns, Physicians', Pregnancy, Rubella diagnosis, Surveys and Questionnaires, Syphilis diagnosis, Toxoplasmosis, Congenital diagnosis, United States, Fetal Diseases diagnosis, Infant, Newborn, Diseases diagnosis, Neonatologists statistics & numerical data
- Abstract
Objective: To describe the clinical approach used by neonatologists for diagnosis of congenital/perinatal infections (CPI); no such data currently exist., Study Design: A national survey regarding the diagnosis of toxoplasma, syphilis, rubella, cytomegalovirus, and herpes simplex virus (HSV) infection in neonates., Result: We received 553 (11%) responses. Central nervous system calcification or hydrocephalus was the commonest trigger to pursue a CPI diagnosis (98%); maternal history was the least frequent (67%). Four hundred twenty-two (76%) used general screening such as "TORCH titer screen" (57%) or total IgG or IgM (39%). Further evaluation targeted known clinical sequelae; but cerebrospinal fluid testing was used in only 65% of those suspected of having HSV or syphilis. Fifty-six percent chose a treponemal instead of a non-treponemal test for syphilis. Multivariable analyses did not identify factors associated with the clinical diagnostic approach., Conclusion: We observed clinically important deviations from CPI diagnostic test recommendations in a national cohort of neonatologists.
- Published
- 2019
- Full Text
- View/download PDF
24. Early onset sepsis calculator-based management of newborns exposed to maternal intrapartum fever: a cost benefit analysis.
- Author
-
Gong CL, Dasgupta-Tsinikas S, Zangwill KM, Bolaris M, and Hay JW
- Subjects
- Anti-Bacterial Agents therapeutic use, Bacteremia drug therapy, Female, Fever, Humans, Infant, Newborn, Neonatal Sepsis diagnosis, Neonatal Sepsis economics, Pregnancy, Pregnancy Complications, Anti-Bacterial Agents economics, Cost-Benefit Analysis, Decision Trees, Neonatal Sepsis drug therapy
- Abstract
Objective: To determine potential net monetary benefit of an early onset sepsis calculator-based approach for management of neonates exposed to maternal intrapartum fever, compared to existing guidelines., Study Design: We performed a cost-benefit analysis comparing two management approaches for newborns >34 weeks gestational age exposed to maternal intrapartum fever. Probabilities of sepsis and meningitis, consequences of infection and antibiotic use, direct medical costs, and indirect costs for long-term disability and mortality were considered., Results: A calculator-based approach resulted in a net monetary benefit of $3998 per infant with a 60% likelihood of net benefit in probabilistic sensitivity analysis. Our model predicted a 67% decrease in antibiotic use in the calculator arm. The absolute difference for all adverse clinical outcomes between approaches was ≤0.6%., Conclusions: Compared to existing guidelines, a calculator-based approach for newborns exposed to maternal intrapartum fever yields a robust net monetary benefit, largely by preventing unnecessary antibiotic treatment.
- Published
- 2019
- Full Text
- View/download PDF
25. Length of Stay and Complications Associated With Febrile Infants <90 Days of Age Hospitalized in the United States, 2000-2012.
- Author
-
Nguyen DK, Friedlander S, Fleischman RJ, and Zangwill KM
- Subjects
- Bacterial Infections complications, Bacterial Infections therapy, Clinical Protocols, Female, Fever etiology, Fever therapy, Hospitalization, Humans, Infant, Infant, Newborn, Male, Practice Guidelines as Topic, Retrospective Studies, United States epidemiology, Virus Diseases complications, Virus Diseases therapy, Bacterial Infections diagnosis, Fever diagnosis, Length of Stay statistics & numerical data, Virus Diseases diagnosis
- Abstract
Objectives: It is not known how changes in the epidemiology of serious bacterial infection (SBI) and greater availability of rapid viral diagnostic tests have impacted the hospital length of stay (LOS) and associated complications among young infants with suspected SBI., Methods: We used national administrative data from the Healthcare Cost and Utilization Project Kids' Inpatient Database and other state-specific data to identify febrile infants <90 days of age hospitalized in 2000, 2003, 2006, 2009, and 2012. We used multivariate analysis to determine LOS, risk factors for prolonged LOS, and complications of care among infants with isolated fever or viral respiratory disease, without concomitant serious infection., Results: We identified 44 875 infants. LOS for each clinical group did not change over time in a clinically significant way. Mean LOS was ≤2 days for approximately two-thirds of all infants and ≥4 days for 11% in each clinical group. Factors associated with longer LOS included age <31 days, critical clinical status, concomitant chronic disease, and the presence of complications ( P < .05). We identified 289 (0.8%) infants with 351 complications of care, 18 (6%) of whom had >1. These infants had longer LOS ( P < .001), and those with chronic disease and older age were at increased risk ( P < .01)., Conclusions: Despite the changing epidemiology of SBI and increased availability of viral diagnostic testing, we did not detect a clinically significant change in LOS for febrile infants with suspected SBI. Complications associated with hospitalization of these infants was associated with increased LOS., Competing Interests: POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose., (Copyright © 2018 by the American Academy of Pediatrics.)
- Published
- 2018
- Full Text
- View/download PDF
26. Impact of AHA's 2007 guideline change on incidence of infective endocarditis in infants and children.
- Author
-
Sakai Bizmark R, Chang RR, Tsugawa Y, Zangwill KM, and Kawachi I
- Subjects
- Adolescent, Child, Child, Preschool, Endocarditis, Bacterial prevention & control, Female, Hospital Mortality trends, Hospitalization trends, Humans, Incidence, Infant, Infant, Newborn, Male, Risk Factors, United States epidemiology, American Heart Association, Endocarditis, Bacterial epidemiology, Inpatients statistics & numerical data, Practice Guidelines as Topic standards, Risk Assessment methods
- Abstract
Use a nationally representative sample to assess impacts of new clinical guidelines issued by the American Heart Association (AHA) in 2007 for many types of invasive procedures, with recommendations for significant decreases in antimicrobial prophylaxis use., Study Design: Interrupted time series analyses of pediatric hospitalizations for Infective Endocarditis (IE), using the Nationwide Inpatient Sample (NIS) ICD-9-CM diagnostic codes, identified IE hospitalizations for patients <18 years old from 2001 to 2012. Changes in IE incidence before and after 2007 AHA guidelines were evaluated, with differences in IE clinical severity assessed using in-hospital mortality and length of stay. Analyses were stratified by pathogen type and age group (0-9 y/o and 10-17 y/o)., Results: With 3,748 patients in the study, we observed rising trends in IE incidence, but no significant difference between pre- and post-guideline. There was a significant trend increase for IE due to viridans group streptococci (VGS) for ages >10 years old, comparing pre-guideline to post-guideline periods, but not in children 0-9 years of age. Neither in-hospital mortality nor length of stay changed significantly during study., Conclusions: The data did not demonstrate an impact of the 2007 guideline changes on overall incidence of pediatric IE. However, a significant increase in disease incidence trend due to VGS was observed for the 10-17 year-old group, compared pre- and post-guideline., (Copyright © 2017 Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
27. Periumbilical Skin and Soft-Tissue Infections Resulting From a Newborn Tracking Device.
- Author
-
Zangwill KM, Belis AD, Ko KJ, and Landholm JM
- Subjects
- California epidemiology, Crime prevention & control, Female, Humans, Male, Patient Identification Systems, Skin Diseases, Infectious etiology, Soft Tissue Infections etiology, Umbilical Cord microbiology, Equipment and Supplies adverse effects, Infant, Newborn, Skin Diseases, Infectious epidemiology, Soft Tissue Infections epidemiology
- Published
- 2017
- Full Text
- View/download PDF
28. Pruritic Rash in a Recent Traveler to Central America.
- Author
-
Nguyen DK, Navarro A, and Zangwill KM
- Subjects
- Adolescent, Animals, Chikungunya Fever blood, Chikungunya Fever drug therapy, Chikungunya Fever urine, Culicidae, Dengue blood, Dengue drug therapy, Dengue urine, Dengue Virus drug effects, Dengue Virus genetics, Dengue Virus pathogenicity, Diagnosis, Differential, Doxycycline therapeutic use, El Salvador, Humans, Male, Neglected Diseases pathology, Rickettsia drug effects, Rickettsia genetics, Rickettsia pathogenicity, Rickettsia Infections pathology, Skin Diseases blood, Skin Diseases drug therapy, Skin Diseases urine, Chikungunya Fever diagnosis, Chikungunya virus, Dengue diagnosis, Neglected Diseases diagnosis, Pruritus, Rickettsia Infections diagnosis, Skin Diseases diagnosis
- Published
- 2015
- Full Text
- View/download PDF
29. A case of munchausen syndrome or central line-associated bloodstream infection? Or both?
- Author
-
Zangwill KM, Marin C, and Vu H
- Subjects
- Adult, Diagnosis, Differential, Female, Humans, Anti-Bacterial Agents administration & dosage, Bacteremia drug therapy, Bacteremia etiology, Catheter-Related Infections complications, Catheter-Related Infections diagnosis, Catheter-Related Infections drug therapy, Catheter-Related Infections psychology, Munchausen Syndrome diagnosis, Munchausen Syndrome physiopathology
- Published
- 2014
- Full Text
- View/download PDF
30. Effectiveness of hospital-based postpartum procedures on pertussis vaccination among postpartum women.
- Author
-
Yeh S, Mink C, Kim M, Naylor S, Zangwill KM, and Allred NJ
- Subjects
- Adult, Female, Humans, Prospective Studies, Treatment Outcome, Pertussis Vaccine, Postpartum Period, Vaccination, Whooping Cough prevention & control
- Abstract
Objective: Pertussis causes significant morbidity among adults, children, and especially infants. Since 2006, pertussis vaccination has been recommended for women after delivery. We conducted a prospective, controlled evaluation of in-hospital postpartum pertussis vaccination of birth mothers from October 2009 through July 2010 to evaluate the effectiveness of hospital-based procedures in increasing postpartum vaccination., Study Design: The intervention and comparison hospitals are private community facilities, each with 2000-6000 births/year. At the intervention hospital, physician opt-in orders for tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) before discharge were implemented in November 2009, followed by standing orders in February 2010. The comparison hospital maintained standard practice. Randomly selected hospital charts of women after delivery were reviewed for receipt of Tdap and demographic data. We evaluated postpartum Tdap vaccination rates and conducted multivariate analyses to evaluate characteristics that are associated with vaccination. We reviewed 1264 charts (658 intervention hospital; 606 comparison hospital) from women with completed deliveries., Results: Tdap postpartum vaccination was 0% at both hospitals at baseline. In the intervention hospital, the introduction of the opt-in order was followed by an increase in postpartum vaccination to 18%. The introduction of the standing order approach was followed by a further increase to 69% (P < .0001). No postpartum Tdap vaccinations were documented in the comparison hospital. Postpartum Tdap vaccination in the intervention hospital did not differ by demographic characteristics., Conclusion: In-hospital ordering procedures substantially increased Tdap vaccination coverage in women after delivery. Opt-in orders increased coverage that increased substantially with standing orders., (Copyright © 2014 Mosby, Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
31. Cost-benefit analysis of hospital based postpartum vaccination with combined tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap).
- Author
-
Ding Y, Yeh SH, Mink CA, Zangwill KM, Allred NJ, and Hay JW
- Subjects
- Adult, Cost-Benefit Analysis, Decision Trees, Diphtheria-Tetanus-acellular Pertussis Vaccines adverse effects, Female, Humans, Infant, Mothers, Postpartum Period, United States, Vaccination economics, Whooping Cough economics, Whooping Cough prevention & control, Whooping Cough therapy, Diphtheria-Tetanus-acellular Pertussis Vaccines administration & dosage, Diphtheria-Tetanus-acellular Pertussis Vaccines economics
- Abstract
Objective: To assess the economic benefits associated with hospital-based postpartum Tdap (combined tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis) vaccination., Methods: A decision tree model was constructed to calculate the potential cost-benefit of this strategy from both a health care system and a societal perspective. Probabilities and costs were derived from published literature, data reported to Centers for Disease Control and Prevention, and recommendations from expert panels. The maternal vaccination protection period for infants was defined as 7 months, and 10 years of waning immunity following Tdap for birth mothers was estimated in the model. All cost estimates were inflated to year 2012 US dollars and discounted at a 3% annual discount rate., Results: In the base case from a societal perspective, the expected costs per vaccinated and unvaccinated mother were estimated at $129.27 and $187.97, respectively, suggesting an expected net benefit of $58.70 per vaccinated mother. The overall societal benefits in the cohort of 3.6 million U.S. birth mothers ranged from $52.8-126.8 million, depending on the vaccination coverage level. If including direct medical costs only, the strategy would not generate net savings from a health care system perspective. Annual incidence of pertussis in birth mothers and Tdap efficacy exhibited substantial impact on the model as shown in one-way and two-way sensitivity analyses., Conclusions: Although postpartum Tdap vaccination is not cost-beneficial from a health care system perspective in the base case, this strategy is likely to generate net benefits from a societal perspective., (Copyright © 2013 Elsevier Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
32. Cat scratch disease and other Bartonella infections.
- Author
-
Zangwill KM
- Subjects
- Angiomatosis, Bacillary diagnosis, Angiomatosis, Bacillary microbiology, Angiomatosis, Bacillary therapy, Cat-Scratch Disease diagnosis, Cat-Scratch Disease therapy, Environmental Microbiology, Humans, Syndrome, Bartonella physiology, Cat-Scratch Disease microbiology, Cat-Scratch Disease pathology
- Abstract
First described in 1931, cat scratch disease remains the most commonly identified clinical syndrome associated with Bartonella infection. Over the last 20 years, however, the discovery and use of modern diagnostic tests has greatly expanded our understanding of the pathogenesis, clinical spectrum, and treatment options for Bartonella infections of all types. Indeed, each varies substantially depending on the infecting species and the immune status of the host.
- Published
- 2013
- Full Text
- View/download PDF
33. Evaluation of diagnostic and therapeutic approaches for suspected influenza A(H1N1)pdm09 infection, 2009-2010.
- Author
-
Vijayan V, Jing J, and Zangwill KM
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Antiviral Agents administration & dosage, Child, Child, Preschool, Cohort Studies, Humans, Infant, Influenza, Human epidemiology, Inpatients, Los Angeles epidemiology, Middle Aged, Oseltamivir administration & dosage, Outpatients, Pandemics, Patient Compliance, Retrospective Studies, Young Adult, Antiviral Agents therapeutic use, Influenza A Virus, H1N1 Subtype, Influenza, Human diagnosis, Influenza, Human drug therapy, Oseltamivir therapeutic use
- Abstract
To assess adherence to real-time changes in guidelines for influenza diagnosis and use of oseltamivir during the 2009 influenza A(H1N1) pandemic, we reviewed medical records of patients with confirmed or suspected influenza-like illness (ILI) and those with no viral testing in a large Los Angeles (California, USA) hospital. Of 882 tested patients, 178 had results positive for influenza; 136 of the remaining patients received oseltamivir despite negative or no results. Oseltamivir use was consistent with national recommendations in >90%. Of inpatients, children were less likely than adults to have ILI at testing and to receive oseltamivir if ILI was found. Of outpatients, children were more likely to have positive test results; 20% tested did not have ILI or other influenza signs and symptoms. Twenty-five of 96 test-positive patients and 13 of 19 with lower respiratory tract disease were, inappropriately, not treated. Variations between practice and national recommendations could inform clinical education in future influenza seasons.
- Published
- 2012
- Full Text
- View/download PDF
34. Paralytic syndromes in children: epidemiology and relationship to vaccination.
- Author
-
Zangwill KM, Yeh SH, Wong EJ, Marcy SM, Eriksen E, Huff KR, Lee M, Lewis EM, Black SB, and Ward JI
- Subjects
- Adolescent, Child, Child, Preschool, Cohort Studies, Female, Humans, Incidence, Infant, Infant, Newborn, Influenza Vaccines adverse effects, Male, Meningococcal Vaccines adverse effects, Prevalence, Retrospective Studies, Severity of Illness Index, Paralysis epidemiology, Paralysis etiology, Poliomyelitis epidemiology, Poliomyelitis etiology, Poliovirus Vaccine, Oral adverse effects
- Abstract
Acute flaccid paralysis is a standard outcome for detection of poliomyelitis globally and an ongoing potential vaccine-associated adverse event concern for polio, influenza, and meningococcal vaccines. No systematic population-based data on the epidemiologic and clinical features of this condition, or its potential association with immunization, have been reported from the United States. The present retrospective cohort study of acute flaccid paralysis in the Southern and Northern California Kaiser Permanente Health Care Plans was conducted using computerized diagnosis data and medical record review of potential cases among children aged 1 month to <15 years and diagnosed from January 1, 1992 through December 31, 1998. In all, 3297 potential cases were identified; of these, 2682 cases (81%) did not meet the case definition, and of the remaining 615 cases, 245 (7% of the total) were included. The incidence of disease was 1.4 per 100,000 children/year (95% confidence interval = 1.2-1.6); predicting approximately 844 children/year in the United States. Disease incidence did not vary with season or sex, varied inversely with age, and declined 28% during the study period. No cases of vaccine-associated acute flaccid paralysis were identified. In nonendemic countries, ongoing acute flaccid paralysis surveillance is often conducted, because of the risk of poliovirus importation, but this practice may be difficult to justify, given low disease incidence and breadth of clinical presentation., ((c) 2010 Elsevier Inc. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
35. Compliance with multiple-dose vaccine schedules among older children, adolescents, and adults: results from a vaccine safety datalink study.
- Author
-
Nelson JC, Bittner RC, Bounds L, Zhao S, Baggs J, Donahue JG, Hambidge SJ, Jacobsen SJ, Klein NP, Naleway AL, Zangwill KM, and Jackson LA
- Subjects
- Adolescent, Adult, Child, Child, Preschool, Cohort Studies, Drug Administration Schedule, Female, Humans, Male, Medicaid, Middle Aged, Retrospective Studies, United States, Young Adult, Chickenpox Vaccine administration & dosage, Hepatitis A Vaccines administration & dosage, Hepatitis B Vaccines administration & dosage, Immunization Programs standards, Medication Adherence
- Abstract
Objectives: We studied compliance with multiple-dose vaccine schedules, assessed factors associated with noncompliance, and examined timeliness of series completion among older children, adolescents, and adults., Methods: We conducted a large, multisite, retrospective cohort study of older children, adolescents, and adults in the Vaccine Safety Datalink population from 1996 through 2004. We quantified the rates of completion of all required doses for varicella, hepatitis A, and hepatitis B vaccines according to their recommended schedules., Results: Among those who received a first dose of varicella (n = 16 075), hepatitis A (n = 594 917), and hepatitis B (n = 590 445) vaccine, relatively few completed the series (55%-65% for hepatitis B vaccine and 40%-50% for hepatitis A and varicella vaccines in most age groups). Compliance was lowest among adolescents (35.9%) and Medicaid recipients (29.7%) who received varicella vaccine and among younger adult age groups who received hepatitis A vaccine (25%-35% across those age groups). Even among series completers, there was a relatively long interval of undervaccination between the first and last doses., Conclusions: Compliance with multiple-dose vaccine series among older children, adolescents, and adults is suboptimal. Further evaluations of strategies to improve compliance in these populations are needed.
- Published
- 2009
- Full Text
- View/download PDF
36. Burden of acute gastroenteritis hospitalizations and emergency department visits in US children that is potentially preventable by rotavirus vaccination: a probe study using the now-withdrawn rotashield vaccine.
- Author
-
Tate JE, Curns AT, Cortese MM, Weintraub ES, Hambidge S, Zangwill KM, Patel MM, Baggs JM, and Parashar UD
- Subjects
- Cohort Studies, Cross-Sectional Studies, Dose-Response Relationship, Drug, Female, Humans, Immunization, Secondary, Infant, Male, Retrospective Studies, Rotavirus Vaccines adverse effects, Treatment Outcome, United States, Utilization Review statistics & numerical data, Emergency Service, Hospital statistics & numerical data, Gastroenteritis epidemiology, Gastroenteritis prevention & control, Hospitalization statistics & numerical data, Rotavirus Infections epidemiology, Rotavirus Infections prevention & control, Rotavirus Vaccines therapeutic use
- Abstract
Background: With the implementation of a new rotavirus immunization program in the United States in 2006, determining the potential health benefits of rotavirus vaccination is important. We estimated the burden of acute gastroenteritis hospitalizations and emergency department visits in US children that are potentially preventable by rotavirus vaccination., Methods: We conducted a retrospective cohort analysis of children who in 1998-1999 were eligible to receive a now-withdrawn rotavirus vaccine (RotaShield) and were continuously enrolled in 1 of 6 managed care organizations in the Vaccine Safety Datalink. Estimates of vaccine effectiveness against all-cause gastroenteritis hospitalizations and emergency department visits adjusted according to month of birth, gender, and managed care organizations were calculated as 1 minus the risk ratio of outcomes among children in different dose groups. The burden of acute gastroenteritis prevented by vaccination was compared with the rotavirus burden estimated by 2 previously used indirect methods., Results: The effectiveness of a full 3-dose RotaShield series over a 1-year follow-up period was 83% against all-cause gastroenteritis hospitalizations and 43% against all-cause gastroenteritis emergency department visits. An increasing number of doses improved the effectiveness in preventing gastroenteritis hospitalizations, but no clear trend was observed between number of doses and effectiveness in prevention of gastroenteritis emergency department visits. The proportion of gastroenteritis hospitalizations and emergency department visits prevented by vaccination was substantially greater than the 48% to 53% of year-round hospitalizations and 33% of emergency department visits estimated to result from rotavirus by indirect methods., Conclusions: The withdrawn rotavirus vaccine was highly effective in preventing hospitalizations and emergency department visits for all-cause acute gastroenteritis and the health benefits of vaccination against rotavirus may be greater than previously estimated.
- Published
- 2009
- Full Text
- View/download PDF
37. Evaluation of vaccine coverage for low birth weight infants during the first year of life in a large managed care population.
- Author
-
Batra JS, Eriksen EM, Zangwill KM, Lee M, Marcy SM, and Ward JI
- Subjects
- Age Factors, Bacterial Outer Membrane Proteins administration & dosage, Bacterial Outer Membrane Proteins adverse effects, California, Diphtheria-Tetanus-Pertussis Vaccine administration & dosage, Diphtheria-Tetanus-Pertussis Vaccine adverse effects, Diphtheria-Tetanus-acellular Pertussis Vaccines administration & dosage, Diphtheria-Tetanus-acellular Pertussis Vaccines adverse effects, Female, Haemophilus Vaccines administration & dosage, Haemophilus Vaccines adverse effects, Humans, Immunization Schedule, Infant, Infant, Newborn, Male, Poliovirus Vaccine, Inactivated administration & dosage, Poliovirus Vaccine, Inactivated adverse effects, Polysaccharides, Bacterial administration & dosage, Polysaccharides, Bacterial adverse effects, Retrospective Studies, Infant, Extremely Low Birth Weight, Infant, Low Birth Weight, Infant, Premature, Diseases epidemiology, Infant, Very Low Birth Weight, Managed Care Programs statistics & numerical data, Vaccination statistics & numerical data
- Abstract
Objective: There are few recent population-based assessments of vaccine coverage in premature infants available. This study assesses and compares age- and dose-specific immunization coverage in children of different birth weight categories during the first year of life., Methods: We performed a retrospective cohort analysis of computerized vaccination data from a large managed care organization in southern California. The participants were children born between January 1, 1997, and December 31, 2002, and continuously enrolled from birth to at least 12 months of age in the Southern California Kaiser Permanente health plan. We measured age-specific up-to-date and age-appropriate immunization rates according to birth weight (extremely low birth weight: <1000 g; very low birth weight: 1000-1499 g; low birth weight: 1500-2499 g; normal birth weight: >/=2500 g) for 4 vaccines (hepatitis B, diphtheria and tetanus toxoids with pertussis, Haemophilus influenzae type b, and poliovirus) through the first year of life., Results: We identified 127 833 infants born during the study period and continuously enrolled through the first year of life; 120 048 were normal birth weight infants; 6491 were low birth weight infants; 788 were very low birth weight infants; and 506 were extremely low birth weight infants. Vaccine-specific age-appropriate immunization rates were 3% to 15% lower for low birth weight infants and 17% to 33% lower for extremely low birth weight infants compared with the rates for normal birth weight infants in the first 6 months of life. Extremely low birth weight infants had the lowest age-specific up-to-date immunization levels (5%-31% lower) compared with normal birth weight infants at each age assessed. By 12 months, extremely low birth weight infants still had significantly lower up-to-date levels (87%) compared with very low birth weight, low birth weight, and normal birth weight infants (91%-92%)., Conclusions: Despite recommendations that lower birth weight infants be vaccinated as the same chronological age as normal birth weight infants, extremely low birth weight and very low birth weight infants are immunized at significantly lower rates relative to low birth weight and normal birth weight infants at 2, 4, and 6 months of age. However, by 12 months of age this finding persists only in extremely low birth weight infants.
- Published
- 2009
- Full Text
- View/download PDF
38. A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization.
- Author
-
Zangwill KM, Eriksen E, Lee M, Lee J, Marcy SM, Friedland LR, Weston W, Howe B, and Ward JI
- Subjects
- Age Factors, California, Case-Control Studies, Cohort Studies, Communicable Disease Control methods, Diphtheria-Tetanus-acellular Pertussis Vaccines administration & dosage, Dose-Response Relationship, Drug, Drug-Related Side Effects and Adverse Reactions, Female, Hepatitis B Vaccines administration & dosage, Humans, Immunization Schedule, Infant, Male, Poliovirus Vaccine, Inactivated administration & dosage, Reference Values, Risk Assessment, Sex Factors, Vaccination methods, Vaccines, Combined administration & dosage, Vaccines, Combined adverse effects, Diphtheria-Tetanus-acellular Pertussis Vaccines adverse effects, Hepatitis B Vaccines adverse effects, Poliovirus Vaccine, Inactivated adverse effects, Product Surveillance, Postmarketing, Vaccination adverse effects
- Abstract
Background: Prelicensure studies of diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio virus vaccine suggested that there were higher rates of fever after its administration than when its component antigens were given separately., Methods: We conducted an open, controlled, cohort study to evaluate selected potential adverse events after receipt of diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine in the Southern California Kaiser Permanente Health Care Plan. From April 2003 through June 2005, we identified 61,004 infants who received >or=1 dose of vaccine (120000 total doses). This group was compared with a previous cohort of 58,251 age-, gender-, and medical center-matched infants (116,637 doses) who received diphtheria, tetanus, acellular pertussis vaccine and separate doses of hepatitis B and inactivated poliovirus vaccines from January 2002 through March 2003. We compared the incidence of seizures, medically attended events that were associated with fever, and other selected adverse outcomes., Results: We identified 16 infants (8 with fever) who had a seizure in the diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus cohort and 15 infants (6 with fever) among control subjects in the 8-day period after receipt of any dose of vaccine. The incidence of all seizures or seizures associated with fever was not significantly different between cohorts. The incidence of medically attended events that were associated with fever in the 4-day period after any dose of vaccine was also similar in both cohorts. As well, no significant differences between the diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and control cohorts, were noted in the incidence of allergic reactions within 48 hours of any dose of vaccine, outpatient visits within 21 days, hospitalizations within 21 days, or death within 1 year., Conclusions: We did not observe a statistically significant increase in any of several clinically important safety events after diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccination compared with a historical cohort who received separate component vaccines.
- Published
- 2008
- Full Text
- View/download PDF
39. Incidence of neonatal herpes simplex virus infections in two managed care organizations: implications for surveillance.
- Author
-
Xu F, Gee JM, Naleway A, Zangwill KM, Ackerson B, Eriksen E, Weintraub ES, Hutchins K, Wei F, Berman SM, and Markowitz LE
- Subjects
- Herpes Simplex diagnosis, Herpes Simplex virology, Humans, Incidence, Infant, Newborn, International Classification of Diseases, Medical Records, Population Surveillance, Herpes Simplex epidemiology, Managed Care Programs statistics & numerical data
- Abstract
Objectives: To estimate the incidence of neonatal herpes simplex virus (HSV) infections and to assess the utility of surveillance methods for neonatal herpes in 2 managed care populations., Methods: We identified potential cases using 15 discharge International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9) codes for neonatal HSV and other diseases clinically consistent with this diagnosis. We also searched laboratory databases for positive HSV tests and investigated deaths during the neonatal period. We performed medical chart review using a standardized form. Two pediatric infectious disease specialists reviewed the forms of infants who had a positive HSV test or received a herpes-related diagnosis and made a determination as confirmed, probable, or not a case., Results: Among 270,703 infants born from 1997 to 2002, we identified 737 potential cases and completed medical chart abstraction for 699 (95%). Final review identified 35 confirmed or probable cases of neonatal HSV, and the incidence was 12.9 per 100,000 live births. Only 24 (69%) of the 35 cases were confirmed by laboratory testing. Among the 24 confirmed cases, 22 (92%) received an ICD-9 code of 054.xx or 771.2. Among the 60 infants that received an ICD-9 code of 054.xx or 771.2, only 31 (52%) were confirmed or probable cases of neonatal HSV after final review., Conclusions: About 30% of neonatal HSV cases were not laboratory confirmed. The use of ICD-9 codes of 054.xx and 771.2 was a sensitive but not specific method to identify cases of neonatal herpes.
- Published
- 2008
- Full Text
- View/download PDF
40. Compliance with the recommendations for 2 doses of trivalent inactivated influenza vaccine in children less than 9 years of age receiving influenza vaccine for the first time: a Vaccine Safety Datalink study.
- Author
-
Jackson LA, Neuzil KM, Baggs J, Davis RL, Black S, Yamasaki KM, Belongia E, Zangwill KM, Mullooly J, Nordin J, Marcy SM, and DeStefano F
- Subjects
- Child, Child, Preschool, Cohort Studies, Humans, Infant, Retrospective Studies, Guideline Adherence, Influenza Vaccines administration & dosage
- Abstract
Objectives: Children <9 years of age do not respond optimally to a first dose of trivalent inactivated influenza vaccine, and so 2 doses of trivalent inactivated influenza vaccine are recommended for children <9 years of age who are being vaccinated for the first time. We conducted a population-based retrospective cohort study to evaluate compliance with the 2-dose trivalent inactivated influenza vaccine recommendations., Population and Setting: We evaluated 125,928 children 6 months through 8 years of age who were enrolled in health maintenance organizations in the United States participating in the Vaccine Safety Datalink project and who received their first dose of trivalent inactivated influenza vaccine in the 2001-2002, 2002-2003, or 2003-2004 influenza seasons., Results: Compliance with the 2 dose recommendations varied by age group and influenza season. Among children 6 to 23 months of age, the proportion of first-vaccinated children who received a second vaccination was 44% in 2001-2002, 54% in 2002-2003, and 29% in 2003-2004. Among children 2 to 8 years of age, the corresponding proportions were 15%, 24%, and 12%, respectively. In all seasons, compliance with the second vaccination was highest in children first vaccinated by mid-November., Conclusions: The majority of children who received their first dose of trivalent inactivated influenza vaccine did not complete the 2-dose series. The recently expanded recommendation for universal vaccination of children 6 to 59 months of age and their household contacts will substantially increase the number of children targeted for a first influenza vaccination. Noncompliance with the 2-dose trivalent inactivated influenza vaccine series may be associated with suboptimal protection against infection, which may impact the magnitude of the direct and indirect benefits achieved by the vaccination program.
- Published
- 2006
- Full Text
- View/download PDF
41. Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old.
- Author
-
Hambidge SJ, Glanz JM, France EK, McClure D, Xu S, Yamasaki K, Jackson L, Mullooly JP, Zangwill KM, Marcy SM, Black SB, Lewis EM, Shinefield HR, Belongia E, Nordin J, Chen RT, Shay DK, Davis RL, and DeStefano F
- Subjects
- Cohort Studies, Humans, Infant, Population Surveillance, Regression Analysis, Retrospective Studies, Risk, United States, Vaccines, Inactivated, Influenza Vaccines adverse effects
- Abstract
Context: Beginning with the winter season of 2004-2005, influenza vaccination has been recommended for all children 6 to 23 months old in the United States. However, its safety in young children has not been adequately studied in large populations., Objective: To screen for medically attended events in the clinic, emergency department, or hospital after administration of trivalent inactivated influenza vaccine in children 6 to 23 months old., Design, Setting, and Participants: Retrospective cohort using self-control analysis, with chart review of significant medically attended events at 8 managed care organizations in the United States that comprise the Vaccine Safety Datalink. Participants were all children in the Vaccine Safety Datalink cohort 6 to 23 months old who received trivalent inactivated influenza vaccine between January 1, 1991, and May 31, 2003 (45,356 children with 69,359 vaccinations)., Main Outcome Measure: Any medically attended event significantly associated with trivalent inactivated influenza vaccine in risk windows 0 to 3 days, 1 to 14 days (primary analysis), 1 to 42 days, or 15 to 42 days after vaccination, compared with 2 control periods, one before vaccination and the second after the risk window. All individual ICD-9 codes as well as predefined aggregate codes were examined., Results: Before chart review, only 1 diagnosis, gastritis/duodenitis, was more likely to occur in the 14 days after trivalent inactivated influenza vaccine (matched odds ratio [OR], 5.50; 95% confidence interval [CI], 1.22-24.81 for control period 1, and matched OR, 4.33; 95% CI, 1.23-15.21 for control period 2). Thirteen medically attended events were less likely to occur after trivalent inactivated influenza vaccine, including acute upper respiratory tract infection, asthma, bronchiolitis, and otitis media. After chart review, gastritis/duodenitis was not significantly associated with trivalent inactivated influenza vaccine (matched OR, 4.00; 95% CI, 0.85-18.84 for control period 1; matched OR, 3.34; 95% CI, 0.92-12.11 for control period 2)., Conclusions: In the largest population-based study to date of the safety of trivalent inactivated influenza vaccine in young children, there were very few medically attended events, none of which were serious, significantly associated with the vaccine. This study provides additional evidence supporting the safety of universally immunizing all children 6 to 23 months old with influenza vaccine.
- Published
- 2006
- Full Text
- View/download PDF
42. Compliance with national immunization guidelines for children younger than 2 years, 1996-1999.
- Author
-
Mell LK, Ogren DS, Davis RL, Mullooly JP, Black SB, Shinefield HR, Zangwill KM, Ward JI, Marcy SM, and Chen RT
- Subjects
- Cohort Studies, Databases, Factual, Guidelines as Topic, Health Maintenance Organizations, Humans, Immunization Schedule, Infant, United States, Vaccines, Immunization statistics & numerical data, Patient Compliance statistics & numerical data
- Abstract
Objectives: To evaluate compliance with national immunization guidelines among a large cohort of children cared for at health maintenance organizations (HMOs) and to examine effects on immunization status., Methods: A cohort study of 176134 children born between January 1, 1994, and December 31, 1997, and monitored from birth to the second birthday was performed. Subjects belonged to the Vaccine Safety Datalink Project, a study of children enrolled in 1 of 4 HMOs. Children were continuously enrolled in a HMO for the first 2 years of life. Prevailing recommendations regarding optimal ages of immunization and intervals between doses were applied to define appropriate immunization timing and immunization status. Noncompliance was defined as having a missing or late immunization or an immunization error. Immunization errors included invalid immunizations (too early to be acceptable), extra immunizations (superfluous immunizations or make-up immunizations for invalid immunizations), and missed opportunities resulting in late or missing immunizations., Results: Although 75.4% of children in these HMOs were up to date for all immunizations at 2 years, only 35.6% of children were fully compliant with recommended immunization practices. Less than 8% of children received all immunizations in accordance with strict interpretation of recommended guidelines. Fifty-one percent of children had at least 1 immunization error by age 2 years; 29.7% had a missed opportunity with subsequent late or missing immunization, 20.4% had an invalid immunization, and 11.6% had an extra immunization. Common reasons for noncompliance included missed opportunities for the fourth Haemophilus influenzae type b vaccine (14.6%), invalid fourth diphtheria-tetanus-pertussis/acellular pertussis immunizations (11.0%), and superfluous polio immunizations (9.8%)., Conclusions: Approximately 35.6% of children were compliant with prevailing childhood immunization recommendations from 1996 to 1999. Efforts to improve compliance with guidelines are recommended, to optimize childhood infectious disease prevention.
- Published
- 2005
- Full Text
- View/download PDF
43. Safety of the trivalent inactivated influenza vaccine among children: a population-based study.
- Author
-
France EK, Glanz JM, Xu S, Davis RL, Black SB, Shinefield HR, Zangwill KM, Marcy SM, Mullooly JP, Jackson LA, and Chen R
- Subjects
- Case-Control Studies, Child, Confidence Intervals, Cross-Over Studies, Female, Health Maintenance Organizations, Humans, Infant, Male, Medical Record Linkage, United States, Influenza Vaccines adverse effects, Population Surveillance methods
- Abstract
Background: To our knowledge, there are no published population-based studies on the safety of the inactivated trivalent influenza vaccine among children., Objective: To screen a large population of children for evidence of increased medical visits in the 2 weeks after influenza vaccination compared with 2 control periods. Secondary analyses included shorter risk periods and restricted age categories., Design: Self-control screening analysis. Children vaccinated from January 1, 1993, through December 31, 1999, were randomly divided into 2 equal groups. In group 1, risks of outpatient, emergency department, and inpatient visits during the 14 days after vaccination were compared with the risks of visits in 2 control periods. Significant plausible medically attended events identified in group 1 were then analyzed in group 2, using the same 2 control periods. Medically attended events significant in both groups were considered potentially associated with vaccination and were assessed by medical record review., Setting: Five managed care organizations in the United States., Participants: Children younger than 18 years who received an influenza vaccination in one of the managed care settings (N = 251 600)., Main Outcome Measure: Among vaccinated children seen for a medically attended event, the odds of the visit occurring in the 2 weeks after vaccination vs during 1 of the 2 control periods., Results: Study participants incurred 1165, 230, and 489 different diagnoses during the 14 days after vaccination according to the outpatient, emergency department, and inpatient data, respectively. Four diagnoses were positively associated with the vaccine in both groups 1 and 2: impetigo, dermatitis, uncomplicated diabetes mellitus, and ureteral disorder not otherwise specified. After medical record review, impetigo (9 cases) in children 6 to 23 months old remained significantly associated with vaccination., Conclusion: This large screening safety study did not reveal any evidence of important medically attended events associated with pediatric influenza vaccination.
- Published
- 2004
- Full Text
- View/download PDF
44. Lack of association between hepatitis B birth immunization and neonatal death: a population-based study from the vaccine safety datalink project.
- Author
-
Eriksen EM, Perlman JA, Miller A, Marcy SM, Lee H, Vadheim C, Zangwill KM, Chen RT, DeStefano F, Lewis E, Black S, Shinefield H, and Ward JI
- Subjects
- California epidemiology, Cause of Death, Chi-Square Distribution, Female, Humans, Infant, Newborn, Male, Risk Factors, Hepatitis B prevention & control, Hepatitis B Vaccines adverse effects, Infant Mortality
- Abstract
Background: There have been no population-based studies of the potential association between neonatal death and newborn immunization with hepatitis B vaccine (HBV)., Methods: As part of the Vaccine Safety Datalink Project, we defined a birth cohort at Southern and Northern California Kaiser Permanente Health Plans of more than 350,000 live births from 1993 to 1998 and ascertained all deaths occurring under 29 days of age. We compared the proportions of deaths among birth HBV-vaccinated and unvaccinated newborns and reviewed the causes and circumstances of their deaths. We performed detailed clinical reviews of all HBV-vaccinated neonates who died and a sample of unvaccinated neonates who died and who were matched to vaccinated deaths for days of life, sex, birth year and site of care. To avoid confounding, we categorized the causes of death as either "expected" or "unexpected" and performed a stratified analysis to compare mortality with immunization status., Results: There were 1363 neonatal deaths during the study period. Whereas 67% of the entire birth cohort received HBV at birth, only 72 (5%) of the neonates who died were HBV-vaccinated at birth (P < 0.01). We found no significant difference in the proportion of HBV-vaccinated (31%) and unvaccinated (35%) neonates dying of unexpected causes (P = 0.6). Further we could not identify a plausible causal or temporal relationship between HBV administration and death for the 22 vaccinated neonates who died unexpectedly., Conclusions: A relationship between HBV and neonatal death was not identified.
- Published
- 2004
- Full Text
- View/download PDF
45. Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination.
- Author
-
Zangwill KM and Belshe RB
- Subjects
- Child, Child, Preschool, Humans, Infant, Influenza Vaccines adverse effects, Influenza Vaccines immunology, Influenza, Human immunology, Randomized Controlled Trials as Topic, Vaccines, Attenuated immunology, Vaccines, Attenuated standards, Vaccines, Inactivated immunology, Vaccines, Inactivated standards, Influenza Vaccines administration & dosage, Influenza, Human prevention & control
- Abstract
Increasing use of influenza vaccine in children is expected as this important virus becomes more widely recognized as a major cause of morbidity in young children. Clinicians and third party payers must consider the implications of national vaccine use recommendations, with their current focus on young children, on their practices and on the community at large. Two influenza vaccines are available in the United States, an inactivated, trivalent intramuscular formulation (TIV) which is approved for use among children > or =6 months of age; and a live, attenuated intranasal trivalent preparation (LAIV) indicated for healthy persons 5 to 49 years of age. This review summarizes available data regarding the safety and efficacy of TIV, in comparison with LAIV, with particular attention to children <9 years of age, the population for whom two doses of vaccine are recommended for first time vaccination. It is apparent that relatively few data are available on the safety of TIV in young children, that important age-specific differences in TIV vaccine efficacy exist and that LAIV appears similar to TIV with regard to safety and efficacy in younger children, but no head-to-head comparison of these two licensed products is available.
- Published
- 2004
- Full Text
- View/download PDF
46. Heptavalent pneumococcal vaccine conjugated to outer membrane protein of Neisseria meningitidis serogroup b and nasopharyngeal carriage of Streptococcus pneumoniae in infants.
- Author
-
Yeh SH, Zangwill KM, Lee H, Chang SJ, Wong VI, Greenberg DP, and Ward JI
- Subjects
- Cells, Cultured, Heptavalent Pneumococcal Conjugate Vaccine, Humans, Infant, Meningococcal Vaccines standards, Nasopharynx cytology, Neisseria meningitidis classification, Pneumococcal Infections prevention & control, Pneumococcal Infections transmission, Pneumococcal Vaccines standards, Safety, Serotyping, Streptococcus pneumoniae isolation & purification, Vaccines, Conjugate standards, Bacterial Outer Membrane Proteins immunology, Meningococcal Vaccines therapeutic use, Nasopharynx virology, Neisseria meningitidis immunology, Pneumococcal Infections immunology, Pneumococcal Vaccines therapeutic use, Streptococcus pneumoniae immunology, Vaccines, Conjugate therapeutic use
- Abstract
Background: Streptococcus pneumoniae (Sp) is an important bacterial pathogen in children. Nasopharyngeal (NP) colonization of S. pneumoniae is necessary for person-to-person transmission and often precedes invasive disease., Methods: NP carriage of Sp was studied in 49 infants following administration of a heptavalent pneumococcal conjugate vaccine (PCV) conjugated to the outer membrane protein of serogroup b Neisseria meningitidis (vaccine serotypes: 4, 6B, 9V, 14, 18C, 19F, 23F). The vaccine was administered at 2, 4, 6, and 12 months of age and carriage rates were compared to a concurrent group of 32 infants not given PCV and evaluated over the first 15 months of life., Results: Overall, Sp was isolated in 86/367 (23%) of NP cultures and 49% of infants. Serotype 23F was significantly less prevalent in the PCV group (1.9%) than the control group (16.1%) (P<0.05). Analysis of the proportion of children with prevalent carriage or acquisition of carriage did not differ between groups when evaluated by age or serotype. We noted, however, decreased acquisition and carriage in the vaccine group 1 month following the 12 month dose of PCV for vaccine serotypes (76 and 52% reduction, respectively), but this did not reach statistical significance (P=0.3). Adjustment for age, daycare and antibiotic use by multivariate modeling revealed no difference in carriage of vaccine containing serotypes or non-vaccine serotypes between groups., Conclusion: We did not show a significant effect of this heptavalent PCV on NP carriage. Further study of this issue, including a larger population size, is needed.
- Published
- 2003
- Full Text
- View/download PDF
47. Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants.
- Author
-
Zangwill KM, Greenberg DP, Chiu CY, Mendelman P, Wong VK, Chang SJ, Partridge S, and Ward JI
- Subjects
- Heptavalent Pneumococcal Conjugate Vaccine, Humans, Immunization, Secondary, Infant, Meningococcal Vaccines adverse effects, Pneumococcal Vaccines adverse effects, Time Factors, Vaccines, Conjugate adverse effects, Haemophilus Infections immunology, Meningococcal Vaccines therapeutic use, Pneumococcal Infections immunology, Pneumococcal Vaccines therapeutic use, Vaccines, Conjugate therapeutic use
- Abstract
Objective: To evaluate the safety and immunogenicity of two lots of a heptavalent Streptococcus pneumoniae conjugate vaccine (PCV) containing seven capsular polysaccharide serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F) conjugated to the outer membrane complex of Neisseria meningitidis serogroup B (OMPC) and administered to infants at 2, 4, 6, and 12 months of age., Methods: One hundred twenty infants were randomly assigned to concurrently receive PCV-OMPC and one of two Haemophilus influenzae type b (Hib) conjugate-DTwP combination vaccines: (1) Hib with a heterologous protein carrier (CRM(197), TETRAMUNE, Group 1) or (2) an experimental Hib-hepatitis b combination vaccine with the homologous carrier (OMPC, Group 2). All infants in Groups 1 and 2 received PCV-OMPC (lot 1) at 12 months of age. Another separate group of 120 infants (Group 3) received a different lot of PCV-OMPC concurrently with Hib-CRM(197) (TETRAMUNE) at 2, 4, and 6 months of age and then were randomized to receive either PCV-OMPC or a 23-valent polysaccharide (PS) pneumococcal vaccine at 12 months of age., Results: Each PCV-OMPC lot was generally well tolerated and no vaccine-related serious adverse events were reported. Following the primary series, serotype-specific anti-pneumococcal geometric mean concentrations (GMC) were highest for serotypes 14, 19F, and 4 and lowest for serotypes 6B and 23F. GMC and seroconversion rates in Group 3 (lot 2) were lower than in Group 1 (lot 1) for serotypes 6B, 14, 18C, and 23F. Antibody responses to serotypes 6B, 14, and 18C were significantly lower in Group 2 compared to Group 1. Following a booster dose of PCV-OMPC at 12 months of age, each lot was immunogenic with at least a 5-10-fold increase in antibody levels, and responses were significantly higher among those who received the PS vaccine., Conclusions: PCV-OMPC is generally safe in infants, displays variable immune response by serotype, and concomitant receipt of Hib vaccine with homologous carrier may impact on its immunogenicity.
- Published
- 2003
- Full Text
- View/download PDF
48. Cold-adapted, live attenuated intranasal influenza virus vaccine.
- Author
-
Zangwill KM
- Subjects
- Administration, Intranasal, Child, Child, Preschool, Cold Temperature, Female, Humans, Immunity physiology, Infant, Influenza Vaccines administration & dosage, Male, Risk Assessment, Sensitivity and Specificity, Vaccination methods, Vaccines, Attenuated administration & dosage, Vaccines, Attenuated pharmacology, Influenza Vaccines pharmacology, Influenza, Human prevention & control
- Published
- 2003
- Full Text
- View/download PDF
49. Polio extraimmunization in children younger than 2 years after changes in immunization recommendations.
- Author
-
Mell LK, Davis RL, Mullooly JP, Black SB, Shinefield HR, Zangwill KM, Ward JI, Marcy SM, and Chen RT
- Subjects
- Administration, Oral, Child, Preschool, Female, Health Maintenance Organizations statistics & numerical data, Humans, Immunization Programs statistics & numerical data, Immunization Schedule, Immunization, Secondary statistics & numerical data, Infant, Logistic Models, Male, Poliomyelitis prevention & control, Poliovirus immunology, Poliovirus Vaccine, Inactivated administration & dosage, Poliovirus Vaccine, Oral administration & dosage, Racial Groups, Regression Analysis, Socioeconomic Factors, Health Planning Guidelines, Immunization Programs trends, Immunization, Secondary trends, Poliovirus Vaccines administration & dosage
- Abstract
Objective: To investigate trends over time in polio extraimmunization among children in 4 large health maintenance organizations and to study the association with recent changes in polio immunization policy., Methods: Using 176 169 children who were born after 1994 and enrolled for their first 2 years of life, we assessed rates and trends of polio extraimmunization in the Vaccine Safety Datalink project. We used logistic regression to test the association of extraimmunization with different polio immunization schedules and with sociodemographic characteristics and used Poisson regression to test changes in rates over time., Results: Overall, 10.5% were extraimmunized for poliovirus; children on the all inactivated polio virus or sequential schedule were one half as likely as those on the all oral polio virus schedule to be extraimmunized by 2 years of age. There was a significant decrease in extraimmunization over time, with <5% of children born at the end of 1997 being extraimmunized, compared with >15% at the beginning of 1994., Conclusions: Poliovirus extraimmunization rates have fallen dramatically in association with the change-over to the all inactivated polio virus schedule.
- Published
- 2003
- Full Text
- View/download PDF
50. Lack of association between rotavirus infection and intussusception: implications for use of attenuated rotavirus vaccines.
- Author
-
Chang EJ, Zangwill KM, Lee H, and Ward JI
- Subjects
- Age Factors, Animals, California, Child, Preschool, Diarrhea virology, Epidemiologic Studies, Female, Health Maintenance Organizations, Humans, Infant, Infant, Newborn, Macaca mulatta virology, Male, Retrospective Studies, Risk Assessment, Seasons, Intussusception epidemiology, Intussusception etiology, Rotavirus Infections complications, Rotavirus Vaccines adverse effects
- Abstract
Background: Withdrawal of the tetravalent rhesus-human rotavirus vaccine Rotashield because of its association with intussusception raised concerns about a potential link between natural rotavirus disease and intussusception. Our objective was to determine whether such an association exists., Methods: In the Southern California Kaiser Permanente Health Care Plan, a large health maintenance organization, from October, 1992, to July, 1999, we retrospectively identified by computerized data and medical charts all children <3 years old with intussusception, and from 1997 to 1999 we independently identified by prospective clinical and laboratory evaluation children <3 years old with rotavirus diarrhea. We compared the epidemiologic characteristics of intussusception and rotavirus infection in our study population and evaluated for the presence of both diseases in individual patients., Results: Using computerized data we identified 124 cases of intussusception, 101 (81%) of which were confirmed by medical chart and radiologic reviews. The incidences for infants <1 year old and for children <3 years old were 41 (95% confidence interval, 32 to 55) and 17 (95% confidence interval, 13 to 20) per 100,000 child years, respectively. Between November 1997 and July 1999, we identified 470 cases of rotavirus diarrhea and none had intussusception. Although rotavirus diarrhea had a distinct peak incidence between December and February, intussusception had no apparent seasonality. The age distributions overlapped, but intussusception occurred at an earlier age than rotavirus disease., Conclusions: We found no epidemiologic evidence for an association between intussusception and natural rotavirus infection, but our study was limited by an insufficient number of cases to definitively exclude a causal link. The dramatic winter peak of rotavirus disease had no discernable parallel in the incidence of intussusception. Our data suggest that the association between tetravalent rhesus-human rotavirus vaccine and intussusception may possibly result from the nonhuman rotavirus components of that vaccine.
- Published
- 2002
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.